PATENT CLAIM ANALYSIS

Application Number: 16039403
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-07
Patent Classification: ["514", "254010"]

Abstract:
The present invention relates to methods, and pharmaceutical compositions for the treatment of fibrosis. In particular, the present invention relates to a method of treating fibrosis in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one monoacylglycerol lipase (MGL) inhibitor.

Claim (Index 3):
The method of  claim 1  wherein the fibrosis is selected from the group consisting of dermal scar formation, keloids, liver fibrosis, lung fibrosis, kidney fibrosis, glomerulosclerosis, pulmonary fibrosis, liver fibrosis, renal fibrosis, intestinal fibrosis, interstitial fibrosis, cystic fibrosis of the pancreas and lungs, injection fibrosis, endomyocardial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, and nephrogenic systemic fibrosis.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 95.0
- Lexical Diversity: 1.375
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15512872', '12765103', '13874835', '13963226', '12765048']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7762581479535977
- 35 USC 102 Novelty (BERT): 0.533608420356632
- Combined Prediction Score: 0.7519931751939011
- Mean Citation Score: 217.865378
- Max Citation Score: 367.95587
- Similarity Product: 359.7237831094957

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test